- Home
- IVD
- By Technology Types
- By Diseases Types
- By Product Types
- Research
- Resource
- Distributors
- Company
| Product Name | pAG-DddA Fusion DNA Cytosine Deaminase |
| Catalog No. | IEC-HMM-0113 |
| Description | An engineered Protein A/G–DddA fusion enzyme for antibody-directed deamination of exposed double-stranded DNA in epigenetic footprinting assays. |
| Intended Use | Transcription factor footprinting, targeted chromatin analysis and epigenetic method development. |
| Principle / Technology | The Protein A/G domain binds an antibody localized to a chromatin target, while the DddA domain converts accessible cytosines in nearby double-stranded DNA to uracil. |
| Detection Method | Sequencing-based cytosine-conversion and footprint analysis. |
| Sample Type | Antibody-labeled chromatin or nuclei prepared for deaminase-based epigenetic assays. |
| Performance Range / Specifications | 20 µg or 80 µg packages. |
| Specificity | Antibody-mediated localization concentrates deaminase activity near the selected chromatin-associated protein. |
| Reaction Conditions / Protocol | Bind a validated primary antibody to the chromatin target, recruit the fusion enzyme, perform controlled deamination, and proceed with library preparation and sequencing. |
| Components / Formulation | Purified Protein A/G–DddA fusion enzyme solution. |
| Storage Conditions | Store at −30 to −15°C. |
| Package Specifications | 20 µg; 80 µg. |
| Product Form | Purified fusion enzyme solution. |
| Key Features | Antibody-directed localization; efficient double-stranded DNA cytosine deamination; simplified footprinting workflow. |
| Shipping Conditions | Ship at or below 0°C. |
| Compatibility | Suitable for deaminase-based targeted chromatin and transcription factor footprinting protocols. |
| Application Notes / Precautions | Use a validated antibody and optimize enzyme exposure to balance conversion efficiency and spatial resolution. |
For research use only, not for clinical use.
|
There is no product in your cart. |